Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').

29 Oct 2013

Bending ethical norms to serve patients' interests

A survey among rheumatologists finds many face moral dilemmas when trying to do what's best for their patients in the current health care environment.

29 Oct 2013

Patients with psoriatic arthritis benefit from early aggressive drug treatment, says study

People with a type of arthritis affecting the skin and joints respond significantly better to early, aggressive drug treatment compared to standard care, according to preliminary results presented by a University of Leeds lecturer to a major US conference.

29 Oct 2013

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalationin involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor.

29 Oct 2013

Delaying rheumatoid arthritis treatment could greatly increase likelihood of joint damage

Delaying treatment for rheumatoid arthritis could greatly increase the likelihood that patients will suffer joint damage and experience disability two years out, according to a new study from Vivian Bykerk, M.D. at Hospital for Special Surgery. The research will be presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on October 28 in San Diego.

28 Oct 2013

Socially isolated individuals more likely to experience ongoing pain following THR surgery

Researchers at Hospital for Special Surgery set out to test this hypothesis. They found that people who lacked good social ties were much more likely to experience serious, ongoing pain following total hip replacement surgery two or more years after the procedure.

28 Oct 2013

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Starting with a combination of three traditional disease-modifying antirheumatic drugs (called DMARDs) for treating early rheumatoid arthritis is more cost-effective long term, with comparable benefits, than using either an immediate or step-up approach with anti-tumor necrosis factor (called Anti-TNFs) drugs and methotrexate, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Young, middle-aged fibromyalgia patients report poorer quality of life than older patients

It may seem counterintuitive, but young and middle-aged fibromyalgia patients report worse symptoms and poorer quality of life than older patients, a Mayo Clinic study shows.

28 Oct 2013

DPP-4 inhibitors may reduce risk of autoimmune diseases

Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the risk of autoimmune diseases in these patients, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.

28 Oct 2013

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis who receive early, aggressive therapy with a combination of medications achieve clinical inactive disease status faster than they would with less aggressive therapy, according to new research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Patients with severe rheumatoid arthritis more likely to have heart problems

People with rheumatoid arthritis and other chronic inflammatory conditions are at higher risk of heart disease. Who is in the most danger, why and how best to prevent and detect cardiovascular complications are important questions for physicians and researchers.

28 Oct 2013

Autoimmune link to schizophrenia

Patients with schizophrenia have an increased risk for developing autoimmune diseases, especially if they contract an infection, shows a registry-based study.

24 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

23 Oct 2013

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

The U.S. Food and Drug Administration, in a complaint filed by the U.S. Department of Justice, is seeking a permanent injunction against the dietary supplement manufacturer James G. Cole, Inc., its president, James G. Cole, and its general manager, Julie D. Graves, following the company's repeated distribution of unapproved drugs and adulterated dietary supplements in violation of the Federal Food, Drug, and Cosmetic Act.

23 Oct 2013

Orygen To Manufacture Epirus' Remicade Biosimilar In Brazil

...

22 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

22 Oct 2013

Novozymes Biopharma partners with Almac to provide combined service for drug development

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, is delighted to announce its new collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

22 Oct 2013

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

Bending ethical norms to serve patients' interests

Patients with psoriatic arthritis benefit from early aggressive drug treatment, says study

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Delaying rheumatoid arthritis treatment could greatly increase likelihood of joint damage

Socially isolated individuals more likely to experience ongoing pain following THR surgery

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Young, middle-aged fibromyalgia patients report poorer quality of life than older patients

DPP-4 inhibitors may reduce risk of autoimmune diseases

Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Patients with severe rheumatoid arthritis more likely to have heart problems

Autoimmune link to schizophrenia

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

Orygen To Manufacture Epirus' Remicade Biosimilar In Brazil

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

Novozymes Biopharma partners with Almac to provide combined service for drug development

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in